Clinical trial
Study of Immune Response Modifier in the Treatment of Breast, Ovarian…
NCT00319748 · Masonic Cancer Center, University of Minnesota, Other · Completed
Key facts
| NCT number | NCT00319748 |
|---|---|
| Title | Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers |
| Official title | Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers |
| Lead sponsor | Masonic Cancer Center, University of Minnesota, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Ovarian Cancer, Endometrial Cancer, Cervical Cancer |
| Intervention type | Drug |
| Interventions | 852A |
| Enrollment | 15 |
| Start date | Apr 1, 2006 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2008 |
| First posted | Apr 27, 2006 |
| Last update posted | Aug 26, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: